Regeneron Pharmaceuticals News

Kurse + Charts + Realtime	News + Analysen	Fundamental	Unternehmen	zugeh. Wertpapiere	Aktion
Kurs + Chart	Chart (gross)	News + Adhoc	Bilanz/GuV	Termine	Strukturierte Produkte	Portfolio
Times + Sales	Chartvergleich	Analysen	Schätzungen	Profil		Watchlist
Börsenplätze	Realtime Push	Kursziele	Dividende/GV
Historisch			Analysen

Kurse + Charts + Realtime

News + Analysen

Fundamental

Unternehmen

zugeh. Wertpapiere

Aktion

Kurs + Chart

Chart (gross)

News + Adhoc

Bilanz/GuV

Termine

Strukturierte Produkte

Portfolio

Times + Sales

Chartvergleich

Analysen

Schätzungen

Profil

Watchlist

Börsenplätze

Realtime Push

Kursziele

Dividende/GV

Historisch

Analysen

31.05.22	Regeneron : FDA Accepts Dupixent For Priority Review In Adults With Prurigo Nodularis (RTTNews)
31.05.22	FDA Accepts Dupixent® (dupilumab) for Priority Review in Adults with Prurigo Nodularis (PR Newswire)
31.05.22	Tender offer statement by Third Party (RSS)
27.05.22	Biotech Stocks Facing FDA Decision In June 2022 (RTTNews)
23.05.22	FDA Approves Regeneron's Dupixent To Treat Eosinophilic Esophagitis (RTTNews)
21.05.22	Evkeeza® (evinacumab) Phase 3 Trial Demonstrates 48% LDL-C Reduction in Children with Ultra-rare Form of High Cholesterol (PR Newswire)
20.05.22	FDA Approves Dupixent® (dupilumab) as First Treatment for Adults and Children Aged 12 and Older with Eosinophilic Esophagitis (PR Newswire)
20.05.22	Tender offer statement by Third Party (RSS)
17.05.22	Vyriad, Inc. Raises $29.5M in Series B Funding Led by Renowned Genetics Entrepreneur (PR Newswire)
13.05.22	High School Scientists from Around the World Win Nearly $8M in Awards, Scholarships at Regeneron International Science and Engineering Fair (PR Newswire)
13.05.22	High School Scientists from Around the World Win Nearly $8M in Awards, Scholarships at Regeneron International Science and Engineering Fair (PR Newswire)
11.05.22	Tender offer statement by Third Party (RSS)
04.05.22	Regeneron Pharmaceuticals Q1 Profit Decreases, but beats estimates (RTTNews)
04.05.22	Regeneron Reports First Quarter 2022 Financial and Operating Results (PR Newswire)
03.05.22	Ausblick: Regeneron Pharmaceuticals präsentiert Quartalsergebnisse (finanzen.net)
02.05.22	Regeneron Announces Investor Conference Presentations (PR Newswire)
02.05.22	Form SC TO-T 872589 (RSS)
21.04.22	Form DEFA14A 872589 (RSS)
19.04.22	Regeneron Pharma To Buy Checkmate Pharmaceuticals In $250 Mln All Cash Deal (RTTNews)
19.04.22	SpringWorks, Regeneron To Evaluate Nirogacestat In Combination With REGN5458 In Multiple Myeloma (RTTNews)
19.04.22	Regeneron to Acquire Checkmate Pharmaceuticals and Its Investigational Immune Activator for Potential Use in Multiple Tumor Types (PR Newswire)
19.04.22	Erste Schätzungen: Regeneron Pharmaceuticals stellt Quartalsergebnis zum abgelaufenen Jahresviertel vor (finanzen.net)
19.04.22	Form SC TO-C 872589 (RSS)
14.04.22	Regeneron Says FDA Extends Review Of BLA For REGEN-COV By 3 Months (RTTNews)
14.04.22	U.S. FDA Extends Review of Biologics License Application for REGEN-COV® (casirivimab and imdevimab) for Treatment and Prophylaxis of COVID-19 (PR Newswire)
11.04.22	Form 4 872589 (RSS)
07.04.22	Regeneron, Sanofi: EU Approves Dupixent For Children Aged 6 To 11 Years With Severe Asthma (RTTNews)
07.04.22	Dupixent® (dupilumab) Approved by European Commission for Children Aged 6 to 11 Years with Severe Asthma with Type 2 Inflammation (PR Newswire)
05.04.22	Regeneron to Report First Quarter 2022 Financial and Operating Results and Host Conference Call and Webcast on May 4, 2022 (PR Newswire)
04.04.22	Regeneron : FDA Accepts Dupixent For Priority Review In Patients Aged 12 Yrs And Older With EoE (RTTNews)
04.04.22	FDA Accepts Dupixent® (dupilumab) for Priority Review in Patients Aged 12 Years and Older with Eosinophilic Esophagitis (PR Newswire)
30.03.22	Form 4 872589 (RSS)
28.03.22	Biotech Stocks Facing FDA Decision In April 2022 (RTTNews)
26.03.22	Late-breaking Phase 3 Data at AAD 2022 Show Dupixent® (dupilumab) Significantly Improved Signs and Symptoms of Prurigo Nodularis (PR Newswire)
18.03.22	Form 4 872589 (RSS)
16.03.22	Students Win $1.8 Million at Regeneron Science Talent Search 2022 for Exceptional Research on Neutron Star--Black Hole Systems, Narrowband Radar, and Ribosome Movement in Protein Translation (PR Newswire)
08.03.22	BioNTech, Regeneron To Advance Clinical Development Of FixVac And Libtayo Combination In NSCLC (RTTNews)
28.02.22	Intellia and Regeneron Announce Updated Phase 1 Data Demonstrating a Single Dose of NTLA-2001, Investigational CRISPR Therapy for Transthyretin (ATTR) Amyloidosis, Resulted in Rapid, Deep and Sust... (PR Newswire)
26.02.22	Late-breaking Data at 2022 AAAAI Annual Meeting Show Dupixent® (dupilumab) Significantly Improved Signs and Symptoms of Eosinophilic Esophagitis (PR Newswire)
26.02.22	Late-breaking Phase 3 Data at 2022 AAAAI Annual Meeting Show Dupixent® (dupilumab) Significantly Reduced Itch and Hives in Patients with Chronic Spontaneous Urticaria (PR Newswire)
24.02.22	Form 4 872589 (RSS)
18.02.22	Regeneron, Sanofi To Stop Dupixent Phase 3 Trial In Chronic Spontaneous Urticaria Due To Futility (RTTNews)
18.02.22	Regeneron and Sanofi Provide Update on Ongoing Dupixent® (dupilumab) Chronic Spontaneous Urticaria Phase 3 Program (PR Newswire)
17.02.22	Regeneron Announces Investor Conference Presentations (PR Newswire)
11.02.22	Regeneron: Phase 2 Data In Wet AMD Shows Potential Of Aflibercept 8 Mg Compared To EYLEA (RTTNews)
11.02.22	Regeneron Presents Encouraging Phase 2 Results for High-dose Aflibercept 8 mg in Wet Age-related Macular Degeneration at Angiogenesis Meeting (PR Newswire)
11.02.22	Form SC 13G 872589 (RSS)
10.02.22	Regeneron, Sanofi: FDA Accepts Dupixent Priority Review In Children With Atopic Dermatitis (RTTNews)
10.02.22	FDA Accepts Dupixent® (dupilumab) for Priority Review in Children Aged 6 Months to 5 Years with Moderate-to-severe Atopic Dermatitis (PR Newswire)
04.02.22	Regeneron Pharmaceuticals Q4 Profit Increases, beats estimates (RTTNews)

Aktien Top/Flop

SMI
SPI
SLI
SMIM
DAX
ESTOXX
Dow Jones
S&P 500
NASDAQ 100
Nikkei 225

19.11.24		Zuversicht in New York: NASDAQ 100 mit positivem Vorzeichen
31.10.24		NASDAQ-Handel NASDAQ 100 schlussendlich in Rot
31.10.24		NASDAQ Composite-Handel aktuell: NASDAQ Composite am Donnerstagnachmittag in der Verlustzone
31.10.24		NASDAQ 100-Handel aktuell: Das macht der NASDAQ 100 aktuell
31.10.24		Zurückhaltung in New York: So performt der NASDAQ 100 aktuell
31.10.24		Angespannte Stimmung in New York: NASDAQ Composite liegt mittags im Minus
31.10.24		Zurückhaltung in New York: NASDAQ 100 zum Handelsstart im Minus
31.10.24		Donnerstagshandel in New York: NASDAQ Composite verliert zum Handelsstart

19.11.24

Zuversicht in New York: NASDAQ 100 mit positivem Vorzeichen

31.10.24

NASDAQ-Handel NASDAQ 100 schlussendlich in Rot

31.10.24

NASDAQ Composite-Handel aktuell: NASDAQ Composite am Donnerstagnachmittag in der Verlustzone

31.10.24

NASDAQ 100-Handel aktuell: Das macht der NASDAQ 100 aktuell

31.10.24

Zurückhaltung in New York: So performt der NASDAQ 100 aktuell

31.10.24

Angespannte Stimmung in New York: NASDAQ Composite liegt mittags im Minus

31.10.24

Zurückhaltung in New York: NASDAQ 100 zum Handelsstart im Minus

31.10.24

Donnerstagshandel in New York: NASDAQ Composite verliert zum Handelsstart

Portfolioname Watchlistname
Portfolio
Name
Typ
Valor / ISIN
Börse
Anzahl
Aktueller Kurs
Kurszeit
Kaufpreis
Kaufdatum
Kaufwert	CHF
	Hinzufügen Speichern

Givaudan	3’870.00	1.49 %	K V
Lonza Grp	513.60	1.14 %	K V
Swiss Re	125.25	0.20 %	K V
Holcim	88.46	0.11 %	K V
Kuehne+Nagel Int	210.40	0.00 %	K V
Logitech Intl	68.92	-1.20 %	K V
Part Grp Hldg	1’209.00	-1.47 %	K V
CieFinRichemont	118.90	-1.94 %	K V
Nestle	76.66	-1.94 %	K V
Sonova Hldg	300.40	-5.21 %	K V

Nachrichten zu Regeneron Pharmaceuticals Inc.

Aktien Top/Flop

Regeneron Pharmaceuticals Peer Group Nachrichten

Meistgelesene Nachrichten